IDEA-France.

The closer. Over 2000 patients with stage III colon cancer were randomized to 3 or 6 months of investigator’s choice CAPOX (10%) or mFOLFOX6 (90%). IDEA-France actually hypothesized superiority with 6 months. Overall, 6 was superior to 3 months with disease-free survival (DFS) rates of 76% and 72%, respectively. Once again, this mainly held for the subsets of patients treated with FOLFOX (not CAPOX) and those with higher risk disease (T4 or N2). TBL: 6 is superior to 3 months of adjuvant chemo for patients with stage III colon cancer, with subset analyses consistent with the pooled analysis. | Andre, J Clin Oncol 2018